Emerging therapeutic strategies to enhance HDL function

A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice

(2011) Dacheng Peng et al.   BRITISH JOURNAL OF PHARMACOLOGY

Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis

(2011) Josep Julve et al.   Current Vascular Pharmacology

ETC-216 for coronary artery disease

(2011) Stephen J Nicholls et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

HDL/Apolipoprotein A-I Binds to Macrophage-Derived Progranulin and Suppresses its Conversion into Proinflammatory Granulins

(2011) Hanayuki Okura et al.   Journal of Atherosclerosis and Thrombosis

Anti-oxidant properties of high-density lipoprotein and atherosclerosis

(2010) Eugene A Podrez   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

High-density lipoproteins, platelets and the pathogenesis of atherosclerosis

(2010) Jerzy-Roch Nofer et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

(2010) Evan A. Stein et al.   EUROPEAN HEART JOURNAL

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor

(2009) David Masson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I Milano

(2009) Eric T. Alexander et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

(2009) ESG Stroes et al.   BRITISH JOURNAL OF PHARMACOLOGY

Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

(2009) Ramachandran S. Vasan et al.   CIRCULATION

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

(2009) M. J. Chapman et al.   EUROPEAN HEART JOURNAL

Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function

(2009) Justin M.S. Lee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque

(2008) James A. Shaw et al.   CIRCULATION RESEARCH

Surrogate End Points and FDA Approval

(2008) Bruce M. Psaty et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano

(2008) Giovanni Cimmino et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration

(2008) Borja Ibanez et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo

(2007) Rajesh Puranik et al.   ATHEROSCLEROSIS